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Abstract 
Exposure of cells to conditions of environmental stress (e.g. Heat shock) results in the inducible expression of heat 
shock proteins that function as molecular chaperones or proteases. Heat shock proteins have been classified into 
six major families according to their molecular size: Hsp100, Hsp90, Hsp70, Hsp60, Hsp40, and small heat shock 
proteins. Heat shock proteins (HSPs) function by inducing an ATPase-coupled structural change, followed by 
interactions with diverse co-chaperones and over 200 client proteins implicated in many critical signaling networks. 
These highly expressed HSPs participate in the onset and progression of several human diseases including cancer, 
and their connection with tumorigenesis has facilitated research and clinical trials related to targeting HSPs as a 
novel anti-tumor therapy. The predominant mechanism of chaperone inhibition is through either disruption of the 
HSP association with client protein or an altered binding state that ultimately leads to proteasome-mediated 
degradation. Importantly, chaperone inhibition results in the degradation of several client proteins that play critical 
roles in many of the pathways known as the Hallmarks of Cancer, such as proliferation, angiogenesis, invasion, 
metastasis, and drug resistance. Hypoxia and other stressful stimuli induce HIF expression as well as subsequent 
cellular response, resulting in a cascade of signaling events that induce VEGF expression and angiogenesis. 
Importantly, several critical mediators in this angiogenic signaling pathway, including HIF, VEGF-receptor and 
IL-8/NF-κB are dependent upon Hsp90 for their function. Given that HSP is required for activation of VEGFR, 
PKB, and NFκB, HSP inhibitors can be employed to target multiple signaling molecules of angiogenesis pathway, 
as demonstrated by the potent suppression of VEGF and NO release both in vitro and in vivo with the overall 
outcome of inhibiting tumor angiogenesis. HSPs also participate in invasion and metastasis of tumor so the 
inhibition of HSPs through inhibiting client proteins can also be used as complementary to tumor therapy. 
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INTRODUCTION 
Exposure of cells to conditions of environmental stress— including heat shock, oxidative stress, heavy metals, or 
pathologic conditions, such as ischemia and reperfusion, inflammation, tissue damage, infection, and mutant 
proteins associated with genetic diseases—results in the inducible expression of heat shock proteins that function 
as molecular chaperones or proteases. Molecular chaperones function in protein folding, translocation, and 
refolding of intermediates, proteases, such as the ubiquitin-dependent proteasome, ensure that damaged and short-
lived proteins are degraded efficiently. Consequently, heat shock proteins assist in the recovery from stress either 
by repairing damaged proteins (protein refolding) or by degrading them, thus restoring protein homeostasis and 
promoting cell survival (Jolly and Morimoto, 2000).  
The primary function of the immune response is to distinguish between molecules, usually proteins, 
which are construed as either component of self or non-self molecules likely derived from invading organisms. 
Through the mechanisms of central and peripheral tolerance, the immune response is deterred from attacking cells 
recognized as self (Walker and Abbas, 2002). The case of tumor immunity is however more ambiguous. A 
depressing variety of mechanisms have been found which may account for the ability of tumors to dismiss the 
attentions of the immune response. These include a “loss-of-self ” mechanism in which major histocompatibility 
class I antigens cease to be expressed on the tumor cell surface, thus masking the presence of the tumor proteome 
and evading CD8+ killing (Moller and Hammerling, 1992). Additional mechanisms include the expression by 
cancer cells of Fas ligand that can recognize the presence of proapoptotic Fas on the tumor cell surface and trigger 
programmed cell death of CTL (Chouaib et al., 2002). In addition, the nonmalignant cell populations that migrate 
into the tumor microenvironment appear to play a key role in deterring immunity (Marigo et al., 2008; Terabe et 
al., 2005; Pekarek et al., 1995). Although cytotoxic CD8+ cells progress to and arrest at the periphery of many 
tumors, crossing the tumor capillary wall comprises a barrier to entry of such cells; indeed, ability of CTL to 
penetrate tumors is a favorable prognostic feature (Liu et al., 2012; Fridman et al., 2011; Galon et al., 2006). As 
mentioned, however, tumors also attract a range of normal cells in a process that resembles a normal wound-
healing response. Invading cells include regulatory T lymphocytes (Treg), primary players in peripheral tolerance 
and in the defense against autoimmunity (Beyer et al., 2012; Schmidt et al., 2012). Treg exhibit multiple 
immunosuppressive mechanisms including the secretion of cytokines such as transforming growth factor beta 
(TGFβ) and interleukin-10 (IL-10), the killing of CTL, and inhibition of immune cells through a cell contact 
mechanism (Schmidt et al., 2012). It may be significant that cancer stem cells (CSCs) that account for tumor 
initiation, metastasis, and resistance to many forms of therapy can attract Treg and lead to the expression of 
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immunosuppressive IL-10 (Schatton and Frank, 2009; Visvader, 2009). 
Another class of immunoregulatory cells associated with tumors includes myeloid-derived suppressor 
cells (MDSCs). MDSCs are a heterogeneous population of early myeloid precursors, immature granulocytes, 
macrophages, and DC that can suppress CD4+ and CD8+ T cells, NK and NKT cells and promote development 
of Treg by multiple mechanisms (Marigo et al., 2008). In addition, many tumors contain tumor associated 
macrophages (TAMs) that are also suppressors of tumor immunity through production of IL-10, stimulation of 
Treg, and synthesis of the co-inhibitory factor CTLA-4. Also attracted to the tumor are mesenchymal stem cells 
(MSCs) that can give rise to a tumor-associated fibroblast (TAF) population that supplies growth factors such as 
FGF, TGFβ, and VEGF required for growth and angiogenesis (Kraman et al., 2010). In order to survive under the 
harsh conditions within the tumor microenvironment, cancer cells typically become dependent on stress-inducible 
HSPs to become refractory to chemotherapy, tolerant to hypoxia, resistant to apoptosis, and to suppress antitumor 
immunity, all the while acquiring the properties of invasiveness and metastasis during cancer progression. All the 
above mentioned phenomena in tumor milieu use HSPs directly or indirectly or HSPs are implicated in cancer 
environment development and have been shown to specifically interfere with current antitumor therapies. Not 
surprisingly, inhibition of HSP’s ATPase activity and disruption of ongoing chaperone folding cycles results in 
dissociation, destabilization, and proteasomal degradation of a variety of client proteins, including the cancer-
associated targets Bcl-2, Apaf-1, PKB, and MMP-2 (Jego et al., 2010; Wang et al., 2009). Therefore, the objectives 
of this seminar paper are to review on: the connection between molecular chaperones and tumorigenesis, especially 
focusing on the roles of the molecular chaperone families Hsp90 and Hsp70, and the therapeutic application of 
heat shock proteins against cancer. 
 
GENERAL FEATURES OF HEAT SHOCK PROTEINS 
Types of heat shock proteins 
Heat shock proteins have been classified into six major families according to their molecular size: Hsp100, Hsp90, 
Hsp70, Hsp60, Hsp40, and small heat shock proteins (Jolly and Morimoto, 2000). 
 
Hsp70 Family 
Seventy kilo Dalton heat shock protein (Hsp70) family members are not only responsible for protein 
conformational assembly, but also preventing protein misfolding and aggregation during a variety of post-
translational processes including protein targeting and degradation, membrane translocation, and apoptosis. The 
Hspα group of HSPs includes Hsp70, Hsp71, Hsp72, and GRP78 (BiP). The members of this Hsp70 family 
represent the most highly conserved molecular chaperones. They have two major functional domains: an N-
terminal ATPase-binding domain (ABD) responsible for substrate binding and refolding, and a C-terminal peptide-
binding domain (PBD) to facilitate the release of client protein after ATP hydrolysis. The 78-kDa glucose regulated 
protein (GRP78), also well known as immunoglobulin interacting heavy chain binding protein (BiP), was 
originally found as a major protein for maintaining intracellular homeostasis in endoplasmic reticulum (ER) called 
the unfolded protein response (UPR). High level of GRP78 confers multiple survival advantages to facilitate the 
proliferation of cancer cells through harsh conditions and to acquire chemotherapeutic resistance (Gonzalez-
Gronow et al., 2009; Dong et al., 2008; Lee, 2007; Li and Lee, 2006; Lee, 2001). 
While it is difficult to detect GRP78 expression in normal cells, over-expression of GRP78 can be 
detected in many tumor cell lines and primary tumors, such as breast and prostate cancer cells. In vivo studies 
demonstrate a critical role of GRP78 in tumor growth, metastasis, and angiogenesis in xenograft models and in the 
GRP78 heterozegous mice with partial reduction of GRP78 (Lee, 2007). GRP78 can be detected as a cell surface 
protein in a broad variety of tumor cells by global profiling of the cell surface proteins, suggesting cancer cells 
may have evolved a specific mechanism for presenting GRP78 epitopes on the cell surface (Misra and Pizzo, 2010; 
Gonzalez-Gronow et al., 2009; Misra et al., 2006).  
Seventy two kilo Dalton heat shock protein (Hsp72) is another major heat shock-induced protein capable 
of protecting cells from stressful conditions. Hsp72 can be present at elevated levels in various forms of tumors 
and in many transformed cell lines. Based on more novel findings of roles of Hsp70 from clinical and basic research, 
Hsp70 targeted therapy is clearly an attractive approach for anti-tumor treatment. Considerable progress has been 
made in targeting Hsp70 using small molecule inhibitors in cancer as well as in other protein folding diseases (Li, 
2011).  
 
Hsp90 Family 
The most prevalent members of the Hsp90 family are Hsp90α and Hsp90β isoforms which are expressed by two 
distinct genes whose protein products are mainly cytoplasmic. So far only Hsp90α has been reported to stabilize 
MMP-2 and prevents it from degradation in cancer cells through the interaction between the Hsp90α middle 
domain and the MMP-2 C-terminal hemopexin domain (Song et al., 2010).  
Ninety kilo Dalton heat shock protein inhibition has attracted considerable attention in the past two 
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decades as a promising approach for cancer therapy, leading to degradation of multiple oncogenic client proteins. 
A number of compounds and their derivatives have been shown to bind the ATP binding pocket of Hsp90, which 
prevents ATP hydrolysis and blocks protein folding and assembly. Instead, Hsp90 inhibition results in the targeting 
of its client proteins to a proteosomal degradation pathway (Tapia and Morano, 2010). 
Table 1. Brief summary of the nomenclature, location, and function of the major heat shock protein families. 
Family Organism Location Functions  
Hsp100 E. coli Cytosol Role in stress tolerance; helps the resolubilization 
of heat-inactivated proteins from insoluble 
aggregates 
S. cerevisiae Cytosol 
Hsp90 E. coli Cytosol Role in signal transduction (e.g., interaction with 
steroid hormone receptors, tyrosine kinases, 
serine/ threonine kinases); refolds and maintains 
proteins in vitro; autoregulation of the heat shock 
response; role in cell cycle and proliferation 
S. cerevisiae Cytosol 
Mammals Cytosol/ER 
Hsp70 E. coli Cytosol Roles in lambda phage replication; autoregulation 
of the heat shock response; interaction with 
nascent chain polypeptides; functions in 
interorganellar transport; roles in signal 
transduction; refolds and maintains denatured 
proteins in vitro; role in cell cycle and 
proliferation; antiapoptotic activity; potential 
antigen-presenting molecule in tumor cells. 
S. cerevisiae Cytosol/ER/ 
Mitochondria 
Mammals Cytosol/nucleus/ER/ 
Mitochondria 
Hsp60 E. coli Cytosol Refolds and prevents aggregation of denatured 
proteins in vitro; may facilitate protein 
degradation by acting as a cofactor in proteolytic 
systems; role in the assembly of bacteriophages 
and Rubisco (an abundant protein in the 
chloroplast) 
S. cerevisiae Mitochondria 
Plants Chloroplasts 
Mammals Mitochondria 
Hsp40 E. coli Cytosol Essential cochaperone activity with Hsp70 
proteins to enhance rate of adenosine 
triphosphatease activity and substrate release 
S. cerevisiae 
Mammals 
Cytosol/nucleus 
Small 
HSPs 
E. coli Cytosol Suppresses aggregation and heat inactivation of 
proteins in vitro; confers thermotolerance through 
stabilization of microfilaments; antiapoptotic 
activity 
S. cerevisiae Cytosol 
Mammals Cytosol 
Source: (Jolly and Morimoto, 2000). 
 
Synthesis of heat shock proteins 
Heat shock proteins are vital throughout the whole lifetime of our cells. However, they are needed even more after 
environmental stress, which induces protein damage. In eukaryotic organisms the expression of heat shock protein 
messenger RNA-s is mediated by a family of transcription factors, called heat shock factors. The synthesis of these 
proteins is under control of at least four different heat shock factors (HSF1-4). Heat shock factor 1 (HSF-1) plays 
a major role in heat shock response, while other members of the family are activated after prolonged stress, or 
participate in processes such as embryonic development, or cell differentiation. After stress, damaged proteins 
become abundant and liberate the heat shock factor from its Hsp70/Hsp90 complexes. This process sets the stage 
for the trimerization, nuclear translocation and phosphorylation of HSF-1, which are all pre requisites for its 
binding to the special nucleotide segments, called heat shock elements, in the promoter region of heat shock protein 
genes. All these steps are modulated by numerous co-chaperones of the major heat shock proteins, Hsp70 and 
Hsp90, and most probably by other proteins as well (Morimoto, 1999). 
Following stress body selectively increases some proteins like HSPs synthesis and decreases other 
proteins synthesis i.e. during stress, all the subsequent steps of protein synthesis (RNA splicing, nuclear export 
and translation itself) are blocked and heat shock RNA-s developed various strategies to circumvent these problems. 
Primary transcripts (such as Hsp70 RNA) usually do not contain introns, or the open reading frame encoding the 
protein itself begins after the intron and the initialization may proceed from the intron as well (e.g. Hsp90) 
(Csermely et al., 1998). 
Genes encoding HSPs are transcriptionally regulated by variety of physiologic processes including the 
cell cycle, cell proliferation, and differentiation (Jerome et al., 1993). These observations have led to suggestions 
that Hsp70 and Hsp90 may also have critical functions during cell growth, specifically associated with the cell 
cycle and the proliferative response (Aligue et al., 1994). 
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ROLE OF HEAT SHOCK PROTEINS IN CANCER DEVELOPMENT 
In transformed cells, mechanisms for controlling protein aggregation are critical for preventing cell death that can 
be induced by the increase in cell stress and the ultimate loss of cellular homeostasis. Interestingly, these pathways 
are interrelated with an underlying theme: cancer initiation and progression (Li, 2011). Hsp70 and Hsp90 were 
known to act as anti-apoptotic factors. Hsp90 participates in many key processes in oncogenesis such as self-
sufficiency in growth signals, stabilization of mutant proteins, angiogenesis and metastasis (Laudanski and 
Wyczechowska, 2006).  
 
Function of heat shock proteins in angiogenesis  
High levels of HSP expression are important for cancer cells to survive in a hypoxic tumor microenvironment, 
which is generally attributed to their effects on the transcription factor HIF-1α by mediating its stabilization and/or 
aggregation. HIF-1 is a heterodimer that is composed of both HIF-1α (120 kD) and HIF-1β (91-94 kD). HIF-1α is 
stabilized by Hsp90 in hypoxic conditions and normally degraded by prolyl hydroxylase (PHD), the von Hipple-
Lindau (VHL)/Elongin-C/Elongin-B E3 ubiquitin ligase complex through proteasomes dependent manner (Isaacs 
et al., 2003). 
Ninety kilo Dalton heat shock protein plays a critical role in structural modulation of oncoproteins 
including PKB and BCR-ABL. Hypoxia and other stressful stimuli induce HIF expression as well as subsequent 
cellular response, resulting in a cascade of signaling events that induce VEGF expression and angiogenesis. 
Importantly, several critical mediators in this angiogenic signaling pathway, including HIF, VEGF-receptor and 
IL-8/NF-κB are dependent upon Hsp90 for their function. Receptor Tyrosine Kinase (RTK) activation also 
potentially induces HIF expression via PKB/mTOR-mediated translation pathway. RTKs additionally 
transactivate Ephrin type-A receptor 2 (EphA2), a novel Hsp90 client protein known to be involved in tumor 
angiogenesis. In addition, HIF also promotes the expression of several RTK ligands, for example, hepatocyte 
growth factor (HGF) and TGF-α, as well as RTK receptors including endothelia growth factor receptor (EGFR) 
and insulin-like growth factor receptor (IGFR), thereby reinforcing these signaling interactions. Moreover, Hsp90 
plays a role in NF-κB-induced VEGF expression and regulates downstream effectors. Given that Hsp90 is required 
for activation of VEGFR, PKB and NF-κB, Hsp90 inhibitors can be employed to target multiple signaling 
molecules of angiogenesis pathway, as demonstrated by the potent suppression of VEGF and NO release both in 
vitro and in vivo with the overall outcome of inhibiting tumor angiogenesis (Bohonowych et al., 2010).  
In tumor cells, Signal Transducer and Activator of Transcription-3 (STAT3) is commonly activated and 
blocks apoptosis as wells promotes cell transformation. It is showed that Hsp90 inhibitors can also disrupt HIF-
1α/STAT3 mediated autocrine loop for IL-6 and IGF-I in pancreatic adenocarcinoma cells and the highly 
metastatic pancreatic cells by direct disturbance with the functions of HIF-1α and STAT3. In the same study, 
ELISA data also demonstrated a marked reduction of VEGF-A expression after treatment with 17-allylamino-
geldanamycin (17-AAG), a Hsp90 inhibitor (Li, 2011). Much of the known roles of Hsp90 in angiogenesis are 
shown schematically in Figure 1.  
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Figure 1. Hsp90 inhibitors targeting angiogenic signaling network in cancer. 
Source: (Li, 2011) 
 
Function of heat shock proteins in invasion and metastasis 
Over-expression of heat shock factor 1 (HSF1) and HSPs in tumor cells displayed an increasing trend to invade 
tumor microenvironment and metastasize to distant sites, though molecular mechanisms have not yet fully 
understood. In addition to transcriptional regulation of HSPs expression, recent data also showed that HSF1 is an 
important facilitator for tumor progression. Accumulating research suggests that highly expressed downstream 
factors of HSF1, including Hsp27 and Hsp70, in tumor cells are at least partially responsible for the invasive and/or 
metastatic properties of tumors (Ciocca and Calderwood, 2005) 
Ninety kilo Dalton heat shock protein was detected on the cell surface and in conditioned medium of 
tumor cells, where it acted as a molecular chaperone to assist in the activation of matrix metalloproteinase-2 
(MMP-2), working with a complex of co-chaperone proteins including Hsp90 organizing protein (HOP), leading 
to elevated tumor invasiveness. Accumulating evidences indicate that Hsp90 especially Hsp90α can be expressed 
and function in the extracellular space acting as a molecular chaperone that assist in the maturation of pro-MMP-
2 to its active form by stimulating propeptide cleavage. Activated MMP-2 protease digests many of the major 
extracellular matrix (ECM) components surrounding tumor tissue including fibronectin, laminins, collagens, etc 
thereby facilitating tumor invasion process (Li, 2011).  
 
HEAT SHOCK PROTEIN INHIBITION AS A CANCER TREATMENT 
Cancer is a threat both for human and animal life and is, thus, one of the least understood diseases having no 
effective therapy.Genetic and epigenetic changes characteristic of carcinogenesis make cancer cells antigenically 
distinct from normal human cells. Cancer cells express tumor-specific antigens and tumor-associated antigens 
(Mosolits et al., 2005). At the end of the 1980s, Hsp70, Hsp90, and GRP94 were identified as tumor-specific 
antigens expressed on the surface of various tumor cells and are, therefore,  ideal targets for antitumor therapy 
(Konno et al., 1989)..  
 
Targeting Hsp90-mediated transformational signaling pathways  
Researchers have proposed the six hallmarks of cancer a decade ago to provide a logical and solid framework for 
understanding the biology of cancer. Two emerging hallmarks including reprogramming of energy metabolism 
and evading immune destruction have become additional highlights in the study of tumorigenesis. In addition, two 
enabling characteristics including tumor-promoting inflammation as well as genome instability and mutation have 
been proved to enhance the six core and emerging hallmark capabilities (Li, 2011).  
More importantly, in clinic pathological term “desmoplasia” initially describing the growth of fibrous or 
connective tissue around the tumor lesion has been proven and investigated in the mechanistic study of tumor 
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progression, which further completes our overall consideration of cancer cells not as an “isolated island”, which 
means they have to communicate with and depend on surrounding non-cancerous cells to facilitate tumor 
microenvironment. Microcommunity of cancer is not simply understood by passive composition of bystanders but 
a dynamic microenvironment communication of multiple cell types reciprocally interacting with each other to 
facilitate tumor progression, especially tumor-associated fibroblasts or cancer-associated fibroblasts (TAFs or 
CAFs), a major and critical component of tumor stroma tissue (Tlsty and Coussens 2006; Beacham and Cukierman, 
2005; Kunz-Schughart and Knuechel, 2002;).  
Appreciation of the critical hallmarks and characteristics for the development of cancer will definitely 
modulate the future direction of cancer research and promote our exploration of anti-tumor therapy with potential 
paradigm-shifting strategies. As shown in Figure 1, Hsp90 plays a multifaceted part involved in the acquisition 
and development of the hallmarks of cancer through interacting with many client proteins responsible for essential 
oncogenic transformation. If these client proteins fail to bind a specific ligand or receptor to form a meta-stable 
chaperone-client complex, then they are subjected to ubiquitination and finally degraded by proteasome, providing 
the major theoretical basis of pharmaceutical inhibition of Hsp90-mediated oncogenic signaling pathways. For 
example, Hsp90 inhibitor was reported to inhibit angiogenic signaling pathways either through HIF-dependent or 
-independent manner in the tumor vascularization process (Li, 2011).  
 
 
Figure 2. Current therapeutic targeting of the hallmarks of cancer using Hsp90 inhibitors. 
Source: (Li, 2011)  
Tumor cells activate endothelial cells through secretion of various proangiogenic growth factors including 
VEGF, COX-2, HGF, as well as FGF, which are regulated by hypoxia through the hypoxia inducible factor (HIF) 
and bind to corresponding RTK on dormant endothelial cells. Once endothelial cells become activated, they 
migrate and proliferate to form novel branches from the preexisting blood vessels by secreting the matrix 
metalloproteinases to detach from the extracellular matrix and basement membrane (Li, 2011). 
Major anti-angiogenic effects of Hsp90 inhibitors are most likely associated with down-regulation of HIF 
activity, since the half life of HIF-1α is also controlled in an oxygen-independent way by the competitive binding 
of either Hsp90 to stabilize the protein, or the anchoring protein Receptor for activated C kinase 1 (RACK1) to 
interact with Elongin C and mediate prolyl hydroxylase domain protein 2 (PHD2) and von Hippel-Lindau protein 
(VHL)-independent ubiquitination and degradation of HIF-1α. IL-8/NF-κB signaling axis has been reported to 
upregulate VEGF expression through HIF-independent proangiogenic processes, while suppression of NF-κB 
signaling in animal model of ovarian cancer destroyed tumor angiogenesis with suppression of VEGF and IL-8 
(Huang and Ingber, 2000).  
Furthermore, Hsp90 inhibitors-mediated suppression of NF-κB was observed in several studies. Taken 
together, these data suggested that Hsp90 inhibition reduced NF-κB activation in tumor angiogenesis through IL-
8 mediated signaling pathway. Given that the majority of these oncogenic proteins identified as Hsp90 client 
proteins, Hsp90-directed pharmacological intervention becomes promising for broad suppression of these 
signaling interactions within the tumor progression (Li, 2011).  
Tumor-associated fibroblasts/cancer-associated fibroblasts are a pivotal component in the TAFs/CAFs-
rich stroma contributing to tumorigenesis. Accumulating evidences indicate targeting those fibroblasts may 
facilitate anti-cancer therapy by affecting oncogenic interactions between cancer cells and the assorted cell types 
constituting the tumor microenvironment. Intriguingly, Hsp90 inhibitors suppressed the reactive stroma phenotype 
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in hepatic stellate cells and induced caspase-8-mediated apoptosis via sphingomyelinase- and NF-κB-dependent 
pathways (Myung et al., 2009). 
In addition, MAPK signaling pathways was activated in pancreatic stellate cells and colon cancer through 
upregulation of periostin, a component of extracellular matrix to promote tumor metastasis and invasion, 
suggesting targeting Hsp90-client oncogenic signalings may represent a novel approach for anti-stroma regimen 
in the future (Erkan et al., 2007; Bao et al., 2004). 
 
Small molecule inhibitors and their role in cancer treatment  
Almost two decades ago, Whitesell et al. firstly demonstrated Hsp90-involved heteroprotein complex formation 
was required for v-src-mediated morphologic transformation and benzoquinone ansamycins such as Geldanamycin 
(GA), can inhibit Hsp90-src through competitive-binding to Hsp90 (Whitesell et al., 1994). 
Recently, Roué et al. (2011) reported the Hsp90 inhibitor retaspimycin hydrochloride restored drug 
sensitivity in proteasome inhibitor bortezomib-resistant aggressive mantle cell lymphoma (MCL). In their study, 
one of Hsp70 family members, BiP/GRP78 was up-regulated in aggressive B-cell malignancies including MCL 
and was responsible for constitutive or induced-bortezomib resistance. Retaspimycin hydrochloride in 
combination with bortezomib dissociated Hsp90-BiP/GRP78 complex, causing the latter to be depleted thus 
affecting the UPR and restoring apoptosis (Roué et al., 2011). These findings added a novel function of Hsp90 in 
cancer treatment by inhibition of UPR-related oncogenic phenotypes including drug resistance and evasion of 
apoptosis. With the help of X-ray crystallography and structure-based drug design to improve potency, a second 
class of synthetic Hsp90 inhibitors have been reported, Novartis is a novel Hsp90 inhibitor and has the highest 
affinity for the NH2-terminal ATP-binding site among synthetic small molecule inhibitors. Effects of Novartis 
include inhibition and/or repression of tumor growth in tumor xenografts with a variety of types of human cancers, 
blockage of tumor cell invasion and metastasis both in vitro and in vivo, and depletion of client proteins including 
BCR-ABL, PKB and HIF-α (Eccles et al., 2008).  
Recent studies show impressive synergistic action of Novartis with melphalan, doxorubicin, and 
suberoylanilide hydroxamic acid (SAHA) in multiple myeloma and build the experimental foundation for clinical 
trials (Kaiser et al., 2010). Of notice, cell surface Hsp90 was found on melanoma cells, fibrosarcoma cells, bladder 
cancer cells, prostate cancer cells as well as neuronal cells and play an important role to control cancer cell 
migration independent of intracellular Hsp90 pool function. Intriguingly, extracellular Hsp90α once 
hyperacetylated by HDAC inhibitor acted as a chaperone for MMP-2 to promote tumor cell invasion, suggesting 
inhibition of extracellular hyperacetylated Hsp90α may affect tumor invasion and metastasis (Yang, 2008). 
Table 2. Hsp90 inhibtors in clinical trials 
Hsp90 inhibitor Clinical Trial Phase  Cancer 
Geldanamycin I* Thyroid (hepatotoxicity in vivo 
17-AAG (Tanespimycin) II/III Breast, leukemia, prostate 
17-DMAG I Breast, leukemia 
Retaspimycin hydrochloride I/II/III pancreatic, MCL 
Radicicol I In vitro( no + in vivo results) 
Purine-scaffold inhibitors I Hodgkin’s lymphoma, CLL 
Shepherin - Leukemia (animal model) 
Pyrazoles  - Prostate cancer (in vitro) 
Mesylate  I HT-29 model 
Novartis - Breast, prostate 
Oxime derivative  - Breast (in vitro) 
Novobiocin II Breast and melanoma (in vitro) 
Coumermycin A1  Breast (in vitro) 
Cisplatin I/II/III/IV Head and neck 
Vorinostat/SAHA (HDAC6) I/II Leukemia, head and neck 
Romidepsin II T-cell lymphoma 
*Clinical Trial suspended 
Source: (Li, 2011). 
In order to survive under the harsh conditions within the tumor microenvironment, cancer cells typically 
become dependent on stress-inducible HSPs to become refractory to chemotherapy, tolerant to hypoxia, resistant 
to apoptosis, and to suppress antitumor immunity, all the while acquiring the properties of invasiveness and 
metastasis during cancer progression. To date, more than 200 HSP client proteins have been identified involving 
nearly all fundamental cellular activities and processes, including cell growth, proliferation, and cell survival (Jego 
et al., 2010).  
Interestingly, many cancer-associated proteins have been reported as HSP clients, likely as a mechanism 
for promoting oncogenic transformation. Therefore, targeting HSPs would result in simultaneous inhibition of 
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multiple signaling pathways responsible for modulation of various events involved in cancer progression for a 
broad range of tumor types, such as neoplastic growth, sustained angiogenesis, chemotherapeutic resistance, 
evasion of cell death, and ultimately, invasion and metastasis (Barginear et al., 2008). Although the exact 
molecular mechanism(s) of HSP inhibitors have not yet been fully determined, a significant number of client 
proteins are either part of mechanistic studies (bench) or under evaluation as part of clinical trials (bedside). For 
example, histone deacetylase complex (HDAC) inhibitors as novel anticancer agents are found to hyperacetylate 
Hsp90, causing an increase in its binding to an Hsp90 inhibitor, ultimately showing anti-tumor activity in leukemia 
and prostate cancer (Barginear et al., 2008).  
Glucose-regulated protein 78 kDa (GRP78), also known as immunoglobulin heavy chain binding protein 
(BiP), is a member of the HSP family of molecular chaperones and serves as an unfolded protein response marker. 
GRP78 is involved in cellular adaptation and survival to facilitate tumorigenesis through active interaction with a 
variety of partners/ligands within tumor cells (Dudek et al., 2009). On the basis of shared homology with other 
HSP family proteins, GRP78 is also a molecular target of HDAC inhibitors, resulting in the phosphorylation and 
activation of initiating factor 2α  and an increase in ATF4 and C/EBP homologous protein synthesis, all of which 
are important for progression of certain cancer types (Kahali et al., 2010).  
Thus, overall, HSPs are implicated in cancer and have been shown to specifically interfere with current 
antitumor therapies that target phenotypic responses like apoptosis, necrosis, autophagy, and senescence. Not 
surprisingly, inhibition of Hsp90’s ATPase activity and disruption of ongoing chaperone folding cycles results in 
dissociation, destabilization, and proteasomal degradation of a variety of client proteins, including the cancer-
associated targets Bcl-2, Apaf-1, PKB, and MMP-2 (Jego et al., 2010; Wang et al., 2009).  
Even though clinical trials often show inherent toxicity of Hsp90 inhibitors and strong induction of 
cytoprotective function of Hsp70, a combination of Hsp90 and Hsp70 inhibitors with traditional chemo- and/or 
radio-therapy may provoke tumor regression in a synergistic manner(Jego et al., 2010; Wang et al., 2009). 
 
CONCLUSION AND RECOMMENDATIONS 
Cancer is a threat both for human and animal life and is, thus, one of the least understood diseases having no 
effective therapy. It expresses antigens that are recognized as foreign by the immune system of tumor-bearing 
hosts. In order to survive under the harsh conditions within the tumor microenvironment, cancer cells typically 
become dependent on stress-inducible HSPs to become refractory to chemotherapy, tolerant to hypoxia, resistant 
to apoptosis, and to suppress antitumor immunity, all the while acquiring the properties of invasiveness and 
metastasis during cancer progression. Interestingly, many cancer-associated proteins have been reported as HSP 
clients, likely as a mechanism for promoting oncogenic transformation. Therefore, targeting HSPs would result in 
simultaneous inhibition of multiple signaling pathways responsible for modulation of various events involved in 
cancer progression for a broad range of tumor types, such as neoplastic growth, sustained angiogenesis, 
chemotherapeutic resistance, evasion of cell death, and ultimately, invasion and metastasis. Not surprisingly, 
inhibition of HSPs activity and disruption of ongoing chaperone folding cycles results in dissociation, 
destabilization, and proteasomal degradation of a variety of client proteins, including the cancer-associated targets 
Bcl-2, Apaf-1, PKB, and MMP-2. 
Based on the above conclusive statements, the following points are recommended: 
 Inhibiting Hsp90 in combination with other heat shock proteins, such as Hsp70 and Hsp27, which may 
be an alternative strategy to enhance synergistic cancer therapy with minimum off-target side effect.  
 Additional studies should be accomplished to define the precise molecular mechanism(s) of HSPs which 
will ultimately allow for the identification of reliable biomarkers for monitoring the effects of HSPs 
suppression in vivo.  
 Accumulating evidences suggest alternative locations of HSPs, especially Hsp90 inside or outside of the 
cells, which indicates a unique role as part of a tumor-specific phenotype. Therefore, the use of specific 
cellular or subcellular targeting for chaperones needs to be considered and developed. 
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